Adam's April 2015 Market Outlook on Benzinga.com 04/01/2015
Adam Sarhan, Founder and CEO of Sarhan Capital – #PreMarket Prep for April 1, 2015
Adam Sarhan, Founder and CEO of Sarhan Capital – #PreMarket Prep for April 1, 2015
“It appears that gold is beginning a new up-trend after its recent consolidation,” said Adam Sarhan of Sarhan Capital. “If gold negates this breakout and falls back below $1,440 to $1,430, one would expect sideways action to continue.”
Monday 11.23.15 4pm EST U.S. stocks closed mildly lower Monday as investors eyed fluctuations in oil prices and looked ahead to economic reports in the shortened Thanksgiving holiday week. “I think part of it is we have GDP tomorrow and that has the potential to move markets around a little bit,” said JJ Kinahan, chief strategist…
Want To Buy Leading Stocks….EARLY? Single Stock Ideas… Starting at Only $19/month Advanced Report…. Starting at Only $97/Month Wednesday, June 10, 2015 U.S. and European shares rebounded after several down days on Wednesday, with Wall Street surging on a report that Germany may be satisfied with Greece committing to at least one economic reform in…
PRECIOUS-Gold gains as investors bet on continued Fed stimulus Mon, Oct 28 14:23 PM EDT * Dollar index steadies ahead of Fed meeting * Gains seen likely if Fed delays stimulus tapering * Platinum up 1.7 pct on South African strike (Updates prices) By Marina Lopes and Clara Denina NEW YORK/LONDON, Oct 28 (Reuters) –…
Wednesday 10.14.15 U.S. stocks closed lower Wednesday as investors digested earnings reports and weighed weaker-than-expected data. “The market came into the week pretty overbought and with these earnings reports, (there’s) a little bit of a headwind,” said Bruce Bittles, chief investment strategist at RW Baird. The Dow Jones industrial average closed down about 158 points…
Markets | Wed Oct 21, 2015 3:40pm EDT The S&P 500 and Nasdaq slipped in choppy trading late Wednesday afternoon as insurers and other big healthcare names dropped and Yahoo (YHOO.O) shares fell following disappointing results. Valeant Pharmaceutical’s (VRX.N) U.S.-listed shares dropped sharply, hitting a low of $88.50, after short-seller Citron Research released a report…